MET and gastric cancer: In GC, Aparicio et al. evaluated the efficacy of crizotinib in nine patients (six gastric and three esophageal adenocarcinoma) with MET amplification (≥6 copies), and the best ORR was 55.6% (95% CI 21.2–86.3), with a median PFS of 3.2 months (95% CI 1.0–5.4) and an OS of 8.1 months (95% CI 1.7–24.6) [32].